A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients
Background & objectives: Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have been evaluated in patients with advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib are the first-generation EGFR-TKIs for patients with NSCLC. However, there is...
Main Authors: | Preenumol Thomas, Bini Vincent, Christeena George, Julie Mariam Joshua, K Pavithran, Meenu Vijayan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
Series: | Indian Journal of Medical Research |
Subjects: | |
Online Access: | http://www.ijmr.org.in/article.asp?issn=0971-5916;year=2019;volume=150;issue=1;spage=67;epage=72;aulast=Thomas |
Similar Items
-
Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study
by: Ye Jiang, et al.
Published: (2018-11-01) -
The Cost-effectiveness Analysis of Gefitinib or Erlotinib in the Treatment of
Advanced EGFR Mutant Non-small Cell Lung Cancer Patients
by: Yuxiang MA, et al.
Published: (2013-04-01) -
How to Make the Choice in the Retreatment of EGFR-TKI for Advanced NSCLC Patients Who Benefited from Prior Gefitinib Therapy: the Original Drug or Switching to A Second EGFR-TKI?
by: Chuanhao TANG, et al.
Published: (2013-07-01) -
Flavoured water consumption alters pharmacokinetic parameters and increases exposure of erlotinib and gefitinib in a preclinical study using Wistar rats
by: Aliyah Almomen, et al.
Published: (2020-09-01) -
PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
by: A. U. Kulikov
Published: (2015-03-01)